Life Technologies AG and Febit, Inc. Team to Offer New Solution for Targeted Re-sequencing in Large-scale Genomic Studies

CARLSBAD, Calif. & HEIDELBERG, Germany--(BUSINESS WIRE)--febit holding GmbH and Life Technologies Corporation (NASDAQ: LIFE) today announced that they have entered into a strategic co-marketing agreement to provide a new, scalable solution for researchers conducting targeted re-sequencing studies. In addition, febit will expand its Genomic Services Facility at Heidelberg by adding several Applied Biosystems SOLiDâ„¢ high-throughput sequencing systems and real-time PCR systems. Applied Biosystems is a brand of Life Technologies. As part of the agreement, febit is a member of both the SOLiD System and TaqMan Service Provider Programs. These programs are intended to provide the scientific community with broad access to a comprehensive solution for genomic research using next-generation sequencing.

Back to news